Payment overview · 2025
General Payments
$440.23
23 reported records · 7 companies
Healthcare provider profile · identity verified
Robert Goodman, M. D.
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1760434013
Verified facts
What the public records show
CMS Open Payments records show Robert Goodman, M. D. received $440.23 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 50.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 149 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 334 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 294 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $222.76 | 50.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $79.32 | 18.0% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $52.73 | 12.0% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.15 | 8.2% | 2 | 2025 |
| BIOTRONIK NRO, Inc. | Unresolved — no canonical attribution shown | $19.60 | 4.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.93 | 3.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.74 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $440.23 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $158.03 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $92.65 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $79.32 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.73 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $52.73 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $36.15 | 2 | 2025 |
Source payment records
|
|||||
| Prospera Normalized: prospera |
Device | BIOTRONIK NRO, Inc. | $19.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 294 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 149 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 334 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
54 | 16 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
86 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
75 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
149 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
65 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
334 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
294 | 45 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 508 | 122 |
| Atorvastatin Calcium | Atorvastatin Calcium | 481 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 435 | 103 |
| Metformin Hcl | Metformin Hcl | 431 | 86 |
| Omeprazole | Omeprazole | 401 | 99 |
| Losartan Potassium | Losartan Potassium | 394 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 394 | 88 |
| Ozempic | Semaglutide | 334 | 41 |
| Eliquis | Apixaban | 294 | 45 |
| Furosemide | Furosemide | 278 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 257 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 241 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 232 | 59 |
| Simvastatin | Simvastatin | 221 | 50 |
| Gabapentin | Gabapentin | 173 | 47 |
| Zolpidem Tartrate | Zolpidem Tartrate | 157 | 23 |
| Januvia | Sitagliptin Phosphate | 155 | 23 |
| Sertraline Hcl | Sertraline Hcl | 155 | 28 |
| Lisinopril | Lisinopril | 153 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 33 |
| Jardiance | Empagliflozin | 149 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 145 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 135 | 110 |
| Clopidogrel | Clopidogrel Bisulfate | 134 | 28 |
| Montelukast Sodium | Montelukast Sodium | 133 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 36 |
| Levofloxacin | Levofloxacin | 127 | 94 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 122 | 56 |
| Azithromycin | Azithromycin | 118 | 95 |
| Naproxen | Naproxen | 118 | 51 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 116 | 51 |
| Trazodone Hcl | Trazodone Hcl | 115 | 34 |
| Finasteride | Finasteride | 111 | 27 |
| Enalapril Maleate | Enalapril Maleate | 110 | 22 |
| Famotidine | Famotidine | 110 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 108 | 67 |
| Mupirocin | Mupirocin | 108 | 63 |
| Glimepiride | Glimepiride | 107 | 15 |
| Cefdinir | Cefdinir | 102 | 85 |
| Mounjaro | Tirzepatide | 100 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 99 | 23 |
| Torsemide | Torsemide | 94 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 93 | 58 |
| Cephalexin | Cephalexin | 92 | 58 |
| Synthroid | Levothyroxine Sodium | 86 | 20 |
| Allopurinol | Allopurinol | 84 | 18 |
| Hydrocortisone | Hydrocortisone | 81 | 28 |
| Farxiga | Dapagliflozin Propanediol | 75 | 14 |
| Lidocaine | Lidocaine | 75 | 12 |
| Carvedilol | Carvedilol | 74 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 13 |
| Metformin Hcl Er | Metformin Hcl | 72 | 14 |
| Atenolol | Atenolol | 70 | 14 |
| Trulicity | Dulaglutide | 65 | 11 |
| Cefadroxil | Cefadroxil | 63 | 48 |
| Celecoxib | Celecoxib | 62 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 62 | 20 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 59 | 52 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | 11 |
| Ketoconazole | Ketoconazole | 55 | 17 |
| Linzess | Linaclotide | 54 | 16 |
| Dexlansoprazole Dr | Dexlansoprazole | 51 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Myrbetriq | Mirabegron | 46 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 18 |
| Spironolactone | Spironolactone | 44 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 41 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 40 | suppressed |
| Colchicine | Colchicine | 39 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 39 | 13 |
| Meclizine Hcl | Meclizine Hcl | 38 | 24 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 36 | 36 |
| Potassium Chloride | Potassium Chloride | 36 | 12 |
| Prednisone | Prednisone | 36 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 35 | 11 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 34 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 32 | 11 |
| Ezetimibe | Ezetimibe | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Digoxin | Digoxin | 31 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 30 | 26 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 30 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 29 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 28 | 13 |
| Fluconazole | Fluconazole | 26 | 21 |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 12 |
| Bumetanide | Bumetanide | 24 | suppressed |
| Glipizide | Glipizide | 24 | suppressed |
| Protonix | Pantoprazole Sodium | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Clarithromycin | Clarithromycin | 22 | 19 |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 19 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 22 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Valsartan | Valsartan | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 18 | suppressed |
| Silodosin | Silodosin | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Repaglinide | Repaglinide | 16 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 16 | suppressed |
| Ssd | Silver Sulfadiazine | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Mupirocin | Mupirocin Calcium | 15 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 12 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 13 | 12 |
| Desoximetasone | Desoximetasone | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Istalol | Timolol Maleate | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Naftifine Hcl | Naftifine Hcl | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 11 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Strattera | Atomoxetine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $440.23 · 23 records | Novo Nordisk Inc | AIRSUPRA, ELIQUIS, JARDIANCE, MOUNJARO, NURTEC ODT, Ozempic, Prospera, Rybelsus, VRAYLAR, Wegovy, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error